產品詳情
  • 產品名稱: CRL-1646 FO 小鼠骨髓瘤細胞

  • 產品型號: CRL-1646
  • 產品廠商:其它品牌
  • 產品文檔:
你添加了1件商品 查看購物車
簡單介紹:
簡單介紹 CRL-1646 FO 小鼠骨髓瘤細胞, ATCC 細胞|細胞係|細胞株|腫瘤細胞|細胞,細胞庫管理規範,提供的細胞株背景清楚,提供參考文獻和**培養條件
詳情介紹:

 

CRL-1646 FO 小鼠骨髓瘤細胞

ATCC® Number:  CRL-1646™      Price:  $355.00 
Designations:  FO 
Depositors:   SF de St. Groth 
Biosafety Level: 1 
Shipped:  frozen 
Medium & Serum:  See Propagation 
Growth Properties: suspension
Organism: Mus musculus (mouse) 
Morphology: lymphoblast

 
Source: Disease: plasmacytoma; myeloma
Strain: BALB/c
Cell Type: B lymphoblast;
Permits/Forms: In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location. 
 
Antigen Expression: H-2d
Comments: The line was line created by self fusing Sp2/0 myeloma cells using Sendai virus.
The cells are resistant to 8-azaguanine and do not produce immunoglobulin.
The line can be used a fusion partner for making B cell hybridomas.
Tested and found negative for ectromelia virus (mousepox).
Propagation:  ATCC complete growth medium: The base medium for this cell line is ATCC-formulated Dulbecco's Modified Eagle's Medium, Catalog No. 30-2002. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Temperature: 37.0°C
Atmosphere: air, 95%; carbon dioxide (CO2), 5%
Subculturing:  Medium Renewal: Every 2 to 3 days
Cultures can be maintained by the addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 0.5 to 1 X 10 exp5 viable cells/ml.
Maintain cell density between 1 X 10 exp5 and 1 X 10 exp6 viable cells/ml.
Preservation:  culture medium 95%; DMSO, 5%
Doubling Time:  8 to 10 hrs 
Related Products: Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2002
recommended serum:ATCC 30-2020
References: 1092: de St.Groth SF, Scheidegger D. Production of monoclonal antibodies: strategy and tactics. J. Immunol. Methods 35: 1-21, 1980. PubMed: 7009747
 Related Links  
NCBI Entrez Search 
Make a Deposit 
Frequently Asked Questions 
Material Transfer Agreement 
Technical Support 
Related Cell Culture Products  
 
 

滬公網安備 31010902002433號